Academic Journal
Q1Oncologist
About Oncologist
Oncologist is a scholarly journal published by Oxford University Press. SCImago 2025 lists it in Q1, with an SJR of 1.96 and H-index of 204.
Coverage: 1996-2026. Research categories: Cancer Research (Q1); Medicine (miscellaneous) (Q1); Oncology (Q1).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2024-04-03. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Cancer Immunotherapy and Biomarkers; Lung Cancer Treatments and Mutations; Colorectal Cancer Treatments and Studies; Cancer Treatment and Pharmacology; Breast Cancer Treatment Studies; HER2/EGFR in Cancer Research.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
In Reply: Immune Checkpoint Inhibition in Medulloblastoma: Moving Toward Biologically Informed Strategies
Marta Viana-Pereira, Patrícia Fontão, Rui Manuel Reis
2026-10-01 · DOI: 10.1093/oncolo/oyag387Is There a Role for Immune Checkpoint Inhibitors in High-Risk Medulloblastoma Beyond the Salvage Setting?
Yi-Lun Wang, Chieh-Tsai Wu, Wei-Heng Kao, Tsung-Yen Chang et al.
2026-10-01 · DOI: 10.1093/oncolo/oyag386Precision Oncology at Speed: Workflow Design Determines Clinical Utility in Rapid Molecular Testing for Lung Cancer
Brandon S Sheffield, Katherina Baranova, Parneet Cheema, Miriam A Bredella et al.
2026-10-01 · DOI: 10.1093/oncolo/oyag388Pembrolizumab Combined with Disitamab Vedotin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Colorectal Cancer
Xiaojing Xu, Minzhi Lv, Luoyan Ai, Qing Wang et al.
2026-10-01 · DOI: 10.1093/oncolo/oyag385Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers
Merlijn U J E Graus, Thijmen H T Broekman, Sietske van Nassau, Nicol Pepels-Aarts et al.
2026-09-29 · DOI: 10.1093/oncolo/oyag373Prognostic Disclosure, End-of-Life Communication, and Social Support Associated With Distinct Dyadic Death-Preparedness States Among Cancer Dyads
Fur-Hsing Wen, Chia-Hsun Hsieh, Wen-Chi Chou, Jen-Shi Chen et al.
2026-09-25 · DOI: 10.1093/oncolo/oyag381Overweight BMI compromises survival and correlates with aggressive phenotypes in early-onset but not late-onset rectal cancer patients
Jinlin Cai, Tuoyang Li, Jingrong Weng, Ziye Zhang et al.
2026-09-25 · DOI: 10.1093/oncolo/oyag380Acrokeratosis Paraneoplastica (Bazex Syndrome): A Systematic Review and Quantitative Analysis of 106 Cases
Mustafa Sefa Isin, Mehmet Berke Isler, Amor Khachemoune
2026-09-24 · DOI: 10.1093/oncolo/oyag376Incidence of and Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Thoracic Malignancies: A Prospective Multicenter Study
Yoshihiro Kitahara, Naoki Inui, Takafumi Koyauchi, Kazuhiro Asada et al.
2026-09-23 · DOI: 10.1093/oncolo/oyag377Long-term outcomes and treatment cessation in patients with long term response to first line treatment of metastatic prostate cancer
Monica Meeks, Yasaman Iranmanesh, Hyunsoo Song, Amanda L Blackford et al.
2026-09-23 · DOI: 10.1093/oncolo/oyag375Current Landscape of RAS-Targeted Therapy for Pancreatic Cancer
Y Linda Wu, Benjamin Herzberg, Gulam A Manji
2026-09-23 · DOI: 10.1093/oncolo/oyag379Cannabis Assessment in Oncology Patients – Evaluation Survey: Understanding Usage Patterns in a Rural Radiation Cohort in Kentucky
Evans Amoah, Waleed F Mourad, Marcus E Randall, Eddy S Yang et al.
2026-09-22 · DOI: 10.1093/oncolo/oyag370Dose Response Relationship of Medical Cannabis and Symptom Control in Patients With Pancreatic Cancer: An Analysis of the CANPAN Trial
Arjun Gupta, Kendall Lin, Ella Chrenka, Grace Gilmore et al.
2026-09-21 · DOI: 10.1093/oncolo/oyag374Comparative safety of concurrent adjuvant trastuzumab emtansine versus trastuzumab with radiotherapy in HER2-positive early breast cancer
Mine Aysan, Bahadir Koylu, Ayberk Bayramgil, Dilek Unal et al.
2026-09-21 · DOI: 10.1093/oncolo/oyag372Toxicity Attribution During Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Practical Framework
Jabra Zarka, Daniel S Childs, Miguel Muniz Rincon, Ali Tarhini et al.
2026-09-21 · DOI: 10.1093/oncolo/oyag371Genomic and Transcriptomic Correlates of Deep PSA Response in Patients with Metastatic Androgen Pathway Modulation-Sensitive Prostate Cancer
Rana R McKay, Deepak Kilari, Binyam Yilma, Unnati Jariwala et al.
2026-09-17 · DOI: 10.1093/oncolo/oyag368Chemotherapy Backbone and Outcomes of Immune Checkpoint Inhibitor Combinations Across Solid Tumors: A Pan-Tumor Network Meta-Analysis
Luisana Sisca, Mariam Grazia Polito, Alessio Cortellini, Marco Russano et al.
2026-09-17 · DOI: 10.1093/oncolo/oyag365Real-world treatment patterns in men with metastatic hormone-sensitive prostate cancer in Europe and Asia between 2020 and 2024
Amit D Raval, Sheila Mpima, Vicky Casey, Fil Manuguid et al.
2026-09-17 · DOI: 10.1093/oncolo/oyag369Immune Checkpoint Inhibitors in Resectable and Locoregionally Advanced HNSCC: Past Lessons, Present Evidence, and Future Directions
Kaewta Jeerapradit, Bhumsuk Keam, Nuttapong Ngamphaiboon
2026-09-17 · DOI: 10.1093/oncolo/oyag366The insufficient publication of early-phase clinical trials in oncology
Merel J J Lucassen, Tim Schutte, Alwin D R Huitema, Neeltje Steeghs et al.
2026-09-09 · DOI: 10.1093/oncolo/oyag361Reviews
Community Reviews
Version History
October 4, 2026 at 8:47 pm
September 25, 2026